MRK - Cancer-Focused eFFECTOR Therapeutics Shelves Development Of Lung Cancer Candidate After Disappointing Data | Benzinga
Thursday, eFFECTOR Therapeutics Inc (NASDAQ:EFTR) released topline results from the primary analysis of the Phase 2 KICKSTART trial, which tested tomivosertib or placebo, each combined with Merck & Co Inc’s (NYSE:MRK) Keytruda (pembrolizumab), as a frontline treatment for patients with non-small cell lung cancer with PD-L1 ?50%.
Based on 36 events, the hazard ratio for progression-free survival (PFS, the study’s primary endpoint) using a stratified Cox proportional hazards model was 0.62 in favor of tomivosertib.
The two-sided p-value for PFS, based on a stratified log-rank test, was 0.21, which did not meet the pre-specified threshold of p?0.2.
The median PFS was 13.0 weeks in the tomivosertib plus pembrolizumab arm and 11.7 weeks in the ...